Eli Lilly and Company partnered with Revvity and Schrödinger to expand access to its artificial intelligence (AI) drug discovery models. The initiative, named Lilly TuneLab, makes the company's advanced predictive models available to the broader biotech community.
Access will be provided via the partners' established platforms. These include Revvity's Signals Xynthetica and Schrödinger's LiveDesign.
The collaborations utilize a federated learning approach. This mechanism allows organizations to apply Lilly's models to their research programs while ensuring proprietary data remains secure.
Lilly aims to create a collective intelligence framework. This framework accelerates new medicine discovery by combining diverse experimental data, thereby improving the AI models' predictive performance.